The COVID-19 pandemic caused by SARS-CoV-2 infection is marked by excessive inflammation of several organs, leading to ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

Navitus, the nation’s first transparent, pass-through pharmacy benefit manager (PBM), released its ninth annual Drug Trend ...

Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved ...